Daniela Dias | TechnoPhage, SA

Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102

30 Set 2025 | News

We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now completed.This achievement reflects the dedication of our local teams and, most importantly, the commitment of every patient...

Technophage Initiates Phase 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury

10 Jul 2025 | Sem categoria

Technophage S.A., a clinical-stage biopharmaceutical company focused on developing innovative therapies for areas of unmet medical need, today announces the initiation of a Phase 1b/2a clinical trial to evaluate TZ-161 for the treatment of acute spinal cord...

Technophage has been granted with the ‘COTEC Innovative Status 2025’

20 Jun 2025 | News

Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2025’. COTEC Portugal is the main Portuguese business association for the promotion of business innovation and technological cooperation. The COTEC Innovative Status...

Celebrating 20 Years of Technophage

31 Mar 2025 | News

Twenty years ago, Technophage started as a small startup at the Institute of Molecular Medicine, with a small adventurous team isolating bacteriophages in a lab. Today, we are an international, clinical-stage biopharma with three technological platforms, driving...

TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections

30 Jan 2025 | Press release

TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announce today its intent to establish a strategic...

Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102

Technophage Initiates Phase 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury

Technophage has been granted with the ‘COTEC Innovative Status 2025’

Celebrating 20 Years of Technophage

TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections

Recent news

Search by year

TechnoPhage SA

Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102

Technophage Initiates Phase 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury

Technophage has been granted with the ‘COTEC Innovative Status 2025’

Celebrating 20 Years of Technophage

TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections

Recent news

Search by year

Search by tags